207 related articles for article (PubMed ID: 10802778)
1. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.
Kita M; Goodkin DE; Bacchetti P; Waubant E; Nelson SJ; Majumdar S
Neurology; 2000 May; 54(9):1741-5. PubMed ID: 10802778
[TBL] [Abstract][Full Text] [Related]
2. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
Richert ND; Ostuni JL; Bash CN; Leist TP; McFarland HF; Frank JA
Mult Scler; 2001 Feb; 7(1):49-58. PubMed ID: 11321194
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
Minagara A; Murray TJ;
Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
[TBL] [Abstract][Full Text] [Related]
4. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular interferon beta-1a is effective in Japanese patients with relapsing-remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions.
Saida T; Itoyama Y; Tashiro K; Kira J; Hao Q;
Mult Scler; 2012 Dec; 18(12):1782-90. PubMed ID: 22492130
[TBL] [Abstract][Full Text] [Related]
6. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
Clanet M; Kappos L; Hartung HP; Hohlfeld R;
Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
[TBL] [Abstract][Full Text] [Related]
9. Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
Zivadinov R; Dwyer MG; Markovic-Plese S; Kennedy C; Bergsland N; Ramasamy DP; Durfee J; Hojnacki D; Hayward B; Dangond F; Weinstock-Guttman B
PLoS One; 2014; 9(3):e91098. PubMed ID: 24625687
[TBL] [Abstract][Full Text] [Related]
10. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.
Simon JH; Lull J; Jacobs LD; Rudick RA; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Sheeder J; Miller D; McCabe K; Serra A; Campion MK; Fischer JS; Goodkin DE; Simonian N; Lajaunie M; Wende K; Martens-Davidson A; Kinkel RP; Munschauer FE
Neurology; 2000 Jul; 55(2):185-92. PubMed ID: 10908888
[TBL] [Abstract][Full Text] [Related]
11. Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.
Kinkel RP; Simon JH; O'Connor P; Hyde R; Pace A
Mult Scler Relat Disord; 2014 Nov; 3(6):712-9. PubMed ID: 25891550
[TBL] [Abstract][Full Text] [Related]
12. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
Bermel RA; You X; Foulds P; Hyde R; Simon JH; Fisher E; Rudick RA
Ann Neurol; 2013 Jan; 73(1):95-103. PubMed ID: 23378325
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
Rudick RA; Cookfair DL; Simonian NA; Ransohoff RM; Richert JR; Jacobs LD; Herndon RM; Salazar AM; Fischer JS; Granger CV; Goodkin DE; Simon JH; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munchsauer FE; O'Reilly K; Priore RL; Whitham RH
J Neuroimmunol; 1999 Jan; 93(1-2):8-14. PubMed ID: 10378864
[TBL] [Abstract][Full Text] [Related]
14. Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.
Rudick RA; Kappos L; Kinkel R; Clanet M; Phillips JT; Herndon RM; Sandrock AW; Munschauer FE
Mult Scler; 2011 Mar; 17(3):353-60. PubMed ID: 20965959
[TBL] [Abstract][Full Text] [Related]
15. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
Cohen JA; Cutter GR; Fischer JS; Goodman AD; Heidenreich FR; Kooijmans MF; Sandrock AW; Rudick RA; Simon JH; Simonian NA; Tsao EC; Whitaker JN;
Neurology; 2002 Sep; 59(5):679-87. PubMed ID: 12221157
[TBL] [Abstract][Full Text] [Related]
16. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
Cohen JA; Barkhof F; Comi G; Izquierdo G; Khatri B; Montalban X; Pelletier J; Eckert B; Häring DA; Francis G
J Neurol; 2013 Aug; 260(8):2023-32. PubMed ID: 23632946
[TBL] [Abstract][Full Text] [Related]
18. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
20. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.
Jeffery DR; Chepuri N; Durden D; Burdette J
Mult Scler; 2005 Jun; 11(3):296-301. PubMed ID: 15957510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]